ReviewFrontiers in cardiovascular medicine2022
Assessment and Management of Older Patients With Transthyretin Amyloidosis Cardiomyopathy: Geriatric Cardiology, Frailty Assessment and Beyond.
Review in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Effect of beta-blockade on mortality in patients with cardiac amyloidosis: A systematic review and meta-analysis.ESC heart failure · 2024Pooled it
- Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS-B trial.European journal of heart failure · 2025Trial
- Contemporary Oral Medication Use and Frequency in Patients with Transthyretin Amyloid Cardiomyopathy.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025Trial
- Phenotypic Considerations for Tafamidis Use in a Real-World Cohort of Older Patients with Transthyretin Amyloid Cardiomyopathy.Cardiology and therapy · 2026Article
- Review
- Comprehensive geriatric assessment identifies multidimensional vulnerabilities in older adults with heart failure.Turkish journal of medical sciences · 2026Article
- Skeletal muscle and subcutaneous fat quantity as prognostic indicators in cardiac amyloidosis.European journal of heart failure · 2025Article
- Real-World Characteristics and Treatment Patterns of Patients With Transthyretin Amyloid Cardiomyopathy: Protocol for a Multicountry Disease Registry Study.JMIR research protocols · 2025Article
- Strengthening the Appreciation of Frailty in Patients With Transthyretin Cardiac Amyloidosis.JACC. CardioOncology · 2025Article
- Heart Failure in Older Patients: An Update.Journal of clinical medicine · 2025Review
- Tafamidis in octogenarians with wild-type transthyretin cardiac amyloidosis: an international cohort study.European heart journal · 2025Article
- Frailty in heart failure according to the presence or absence of wild-type transthyretin cardiac amyloidosis.ESC heart failure · 2025Article
- Cross-platform proteomics signatures of extreme old age.GeroScience · 2025Article
- Advances in the Diagnosis and Management of Cardiac Amyloidosis: A Literature Review.Cardiology research · 2024Review
- Gait abnormalities in older adults with transthyretin cardiac amyloidosis.Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis · 2024Article
- Cross-platform proteomics signatures of extreme old age.bioRxiv : the preprint server for biology · 2024Article
- Detection of TTR Amyloid in the Conjunctiva Using a Novel Fluorescent Ocular Tracer.Translational vision science & technology · 2024Article
- Extending the reach of expert amyloidosis care: A feasibility study exploring the staged implementation of a UK amyloidosis network.Clinical medicine (London, England) · 2024Article
- Health care resource use, diagnostic delay and disease burden in transthyretin amyloid cardiomyopathy in Sweden.Annals of medicine · 2023Article
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM).Global heart · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is commonly diagnosed in older adults, in particular the wild-type (ATTRwt), which is regarded as an age-related disease. With an aging population and improved diagnostic techniques, the prevalence and incidence of ATTR-CM will continue to increase. With increased availability of mortality reducing ATTR-CM therapies, patients are living longer. The predominant clinical manifestation of ATTR-CM is heart failure, while other cardiovascular manifestations include arrhythmia and aortic stenosis. Given their older age at diagnosis, patients often present with multiple age-related comorbidities, some of which can be exacerbated by ATTR, including neurologic, musculoskeletal, and gastrointestinal problems. Considerations related to older patient care, such as frailty, cognitive decline, polypharmacy, falls/mobility, functional capacity, caregiver support, living environment, quality of life and establishing goals of care are particularly important for many patients with ATTR-CM. Furthermore, the high cost ATTR treatments has increased interest in establishing improved predictors of response to therapy, with assessment of frailty emerging as a potentially important determinant. Multidisciplinary care inclusive of collaboration with geriatric and elder care medicine specialists, and others such as neurology, orthopedic surgery, electrophysiology and transcatheter aortic valve replacement clinics, is now an important component of ATTR-CM management. This review will examine current aspects of the management of older ATTR-CM patients, including shared care with multiple medical specialists, the emerging importance of frailty assessment and other considerations for using ATTR therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.